GenSight Biologics reports validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency

GenSight Biologics successfully raises €25 million in an oversubscribed private placement with US and European institutional investors

GenSight Biologics launches a capital increase of approximately €25 million by means of an accelerated bookbuilding process

GenSight Biologics Reports Cash Position as of September 30, 2020 and Provides Operational Update

GenSight Biologics Appoints Elsy Boglioli to its Board of Directors

GenSight Biologics Announces Publication of Meta-Analysis Confirming that Spontaneous Recovery in LHON is rare in the Journal of Neuro-Ophthalmology

GenSight Biologics reports new analysis demonstrating statistically significant and clinically meaningful difference between visual outcomes in LUMEVOQ®-treated patients and natural history of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics draws down the €4 million second tranche of bonds from Kreos Capital

GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update